Advertisement

Specialty News

September 13, 2017
September 13, 2017
Diplomat Pharmacy has agreed to acquire Focus Rx Pharmacy Services, a specialty and infusion pharmacy. "This partnership opens growth opportunities...
Diplomat Pharmacy has agreed to acquire Focus Rx Pharmacy Services, a specialty and infusion pharmacy. "This partnership opens growth opportunities, especially in the key markets of New York and New Jersey," noted Phil Rielly, corporate vice president and president of Diplomat Specialty Infusion Group.
MORE
September 13, 2017
September 13, 2017
FDA Commissioner Scott Gottlieb notes that 3 months ago he committed to fully eliminate a backlog of about 200 orphan drug designation requests that...
FDA Commissioner Scott Gottlieb notes that 3 months ago he committed to fully eliminate a backlog of about 200 orphan drug designation requests that were pending review with the agency, and to implement policies that would require FDA to respond to all new designation requests within 90 days of receiving them.
MORE
September 01, 2017
September 06, 2017
Adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to disease-modifying...
Adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs) have a new treatment option with FDA’s approval of sarilumab (Kevzara—Sanofi, Regeneron). The injectable joins tocilizumab (Actemra—Genentech) as the second immunosuppressive agent to block the interleukin-6 (IL-6) receptor.
MORE
September 01, 2017
September 06, 2017
FDA has approved delafloxacin (Baxdela—Melinta Therapeutics) to treat acute bacterial skin and skin structure infections (ABSSSI) caused by...
FDA has approved delafloxacin (Baxdela—Melinta Therapeutics) to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. It is the first fluoroquinolone antibiotic with activity against methicillin-resistant Staphylococcus aureus (MRSA) and, unlike the other fluoroquinolones, is not associated with QT prolongation or photosensitivity. In addition to gram-positive organisms such as MRSA, delafloxacin targets gram-negative pathogens (e.g., Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa).
MORE
August 23, 2017
August 23, 2017
A new leukemia drug from Novartis is being hailed by doctors as a breakthrough, but it could prove among the most expensive therapies ever on the...
A new leukemia drug from Novartis is being hailed by doctors as a breakthrough, but it could prove among the most expensive therapies ever on the market. For a single treatment, the price is expected to reach hundreds of thousands of dollars.
MORE
August 18, 2017
August 18, 2017
A new clinical guideline from the American Gastroenterological Association (AGA) conditionally recommends reactive therapeutic drug monitoring (TDM...
A new clinical guideline from the American Gastroenterological Association (AGA) conditionally recommends reactive therapeutic drug monitoring (TDM) to guide treatment changes in adults with active inflammatory bowel disease (IBD) treated with anti-TNF agents.
MORE
August 18, 2017
August 18, 2017
FDA approved on August 17 inotuzumab ozogamicin (Besponsa—Pfizer) for the treatment of adults with relapsed or refractory B-cell precursor acute...
FDA approved on August 17 inotuzumab ozogamicin (Besponsa—Pfizer) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The targeted therapy is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.
MORE
August 07, 2017
August 07, 2017
PT article
MORE
August 04, 2017
August 04, 2017
FDA has approved a fixed combination of two chemotherapies, daunorubicin and cytarabine (Vyxeos—Jazz Pharmaceuticals), for the treatment of adults...
FDA has approved a fixed combination of two chemotherapies, daunorubicin and cytarabine (Vyxeos—Jazz Pharmaceuticals), for the treatment of adults with two types of acute myeloid leukemia (AML). The two AML types are newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC).
MORE
July 31, 2017
July 31, 2017
Phase II testing suggests that atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, is an effective treatment for...
Phase II testing suggests that atezolizumab, a humanized anti-programmed death-ligand 1 (PD-L1) monoclonal antibody, is an effective treatment for advanced non-small cell lung cancer (NSCLC) in patients with confirmed PD-L1 expression. The BIRCH study compared the drug's effect across samples of patients with different PD-L1 levels.
MORE

Pages